(19)
(11) EP 2 709 989 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
18.04.2018 Bulletin 2018/16

(45) Mention of the grant of the patent:
20.12.2017 Bulletin 2017/51

(21) Application number: 12721852.7

(22) Date of filing: 18.05.2012
(51) International Patent Classification (IPC): 
C07D 239/95(2006.01)
A61P 31/00(2006.01)
 A61K 31/517(2006.01)
(86) International application number:
PCT/EP2012/059234
(87) International publication number:
WO 2012/156498 (22.11.2012 Gazette 2012/47)

(54)

QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND FURTHER DISEASES

CHINAZOLINDERIVATE ZUR BEHANDLUNG VON VIRUSINFEKTIONEN UND WEITEREN ERKRANKUNGEN

DÉRIVÉS DE QUINAZOLINE POUR LE TRAITEMENT DES INFECTIONS VIRALES ET D'AUTRES MALADIES

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME

(30) Priority: 18.05.2011 EP 11166538

(43) Date of publication of application:
26.03.2014 Bulletin 2014/13

(73) Proprietor: Janssen Sciences Ireland UC
Little Island, County Cork (IE)

(72) Inventors:
  • MC GOWAN, David
    B-1150 Brussel (BE)
  • RABOISSON, Pierre, Jean-Marie, Bernard
    B-1331 Rosières (BE)
  • JONCKERS, Tim, Hugo, Maria
    B-2220 Heist-op-den-Berg (BE)
  • LAST, Stefaan, Julien
    B-2547 Lint (BE)
  • EMBRECHTS, Werner
    B-2340 Beerse (BE)
  • PIETERS, Serge, Maria, Aloysius
    NL-4562 AR Hulst (NL)

(74) Representative: Daelemans, Frank F.R. 
Turnhoutseweg 30
2340 Beerse
2340 Beerse (BE)


(56) References cited: : 
WO-A1-98/50370
WO-A1-2009/067081
WO-A2-2008/009078
 WO-A1-2006/050843
WO-A2-2005/007672
   
  • DATABASE HCAPLUS [Online] ACS; XP002662676, retrieved from STN Database accession no. 132:166249 (DN) -& JP 2000 053653 A (SUMITOMO PHARMA; SUMITOMO CHEMICAL CO) 22 February 2000 (2000-02-22)
  • DATABASE HCAPLUS [Online] ACS; XP002662677, retrieved from STN Database accession no. 132:166250 (DN) -& JP 2000 053654 A (SUMITOMO PHARMA; SUMITOMO CHEMICAL CO) 22 February 2000 (2000-02-22)
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).